Considering that the PFK-2 domain is only active in the dimer form, there are three different strategies that can be used to target this enzyme for anti-cancer treatment: (1) selective inhibition of PFK-2 activity; (2) selective inhibition of FBPase-2 activity; and (3) the inhibition of PFK-2 activity by preventing monomeric dimerization. This evidence concerns the gene FBP2 and cancer.